WO2022262841A1 - Salt form and crystal form of spiro compound and preparation method therefor - Google Patents

Salt form and crystal form of spiro compound and preparation method therefor Download PDF

Info

Publication number
WO2022262841A1
WO2022262841A1 PCT/CN2022/099375 CN2022099375W WO2022262841A1 WO 2022262841 A1 WO2022262841 A1 WO 2022262841A1 CN 2022099375 W CN2022099375 W CN 2022099375W WO 2022262841 A1 WO2022262841 A1 WO 2022262841A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal form
compound
formula
angles
ray powder
Prior art date
Application number
PCT/CN2022/099375
Other languages
French (fr)
Chinese (zh)
Inventor
潘志祥
贺海鹰
江志赶
夏建华
Original Assignee
杭州中美华东制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 杭州中美华东制药有限公司 filed Critical 杭州中美华东制药有限公司
Priority to CN202280042743.8A priority Critical patent/CN117677615A/en
Publication of WO2022262841A1 publication Critical patent/WO2022262841A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Definitions

  • the invention discloses a salt form, a crystal form of a spiro compound and a preparation method thereof, and also includes the application of the salt form and the crystal form and medicines for related diseases.
  • NASH nonalcoholic fatty liver disease
  • fructose is quickly phosphorylated by fructokinase Ketohexokinase (KHK) into fructose-1-phosphate.
  • KHK fructokinase Ketohexokinase
  • DNL de novo fat synthesis
  • KHK is the rate-limiting enzyme for the metabolism of fructose to fructose-1-phosphate and is an important target for regulating fructose metabolism. Therefore, inhibiting KHK can effectively inhibit fructose metabolism and its resulting lipid accumulation, oxidative stress, inflammation and insulin resistance, and thus be used for the treatment of NASH.
  • the present invention provides a compound of formula (II),
  • the present invention also provides crystal form A of the compound of formula (II), which is characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2 ⁇ angles: 9.73 ⁇ 0.20°, 11.22 ⁇ 0.20°, 12.66 ⁇ 0.20°, 18.38 ⁇ 0.20°.
  • the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 6.94 ⁇ 0.20°, 9.73 ⁇ 0.20°, 11.22 ⁇ 0.20°, 12.66 ⁇ 0.20°, 15.63 ⁇ 0.20°, 16.62 ⁇ 0.20°, 18.38 ⁇ 0.20°, 20.81 ⁇ 0.20°.
  • the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 6.46 ⁇ 0.20°, 6.94 ⁇ 0.20°, 9.73 ⁇ 0.20°, 11.22 ⁇ 0.20°, 12.66 ⁇ 0.20°, 15.63 ⁇ 0.20°, 16.62 ⁇ 0.20°, 18.38 ⁇ 0.20°, 19.64 ⁇ 0.20°, 20.81 ⁇ 0.20°, 22.51 ⁇ 0.20°, 24.58 ⁇ 0.20°.
  • the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 4.47 ⁇ 0.20°, 6.46 ⁇ 0.20°, 6.94 ⁇ 0.20°, 9.73 ⁇ 0.20°, 11.22 ⁇ 0.20°, 12.25 ⁇ 0.20°, 12.66 ⁇ 0.20°, 15.63 ⁇ 0.20°, 16.62 ⁇ 0.20°, 17.83 ⁇ 0.20°, 18.38 ⁇ 0.20°, 19.64 ⁇ 0.20°, 20.81 ⁇ 0.20°, 22.51 ⁇ 0.20°, 23.59 ⁇ 0.20°, 24.58 ⁇ 0.20°.
  • the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2 ⁇ angles: 4.47°, 6.46°, 6.94°, 9.73°, 10.18°, 11.22°, 12.25°, 12.66 °, 13.30°, 14.30°, 15.63°, 16.62°, 17.27°, 17.83°, 18.38°, 18.67°, 19.37°, 19.64°, 20.06°, 20.41°, 20.81°, 21.72°, 22.51°, 23.59°, 24.58°, 25.11°, 26.44°, 27.41°, 27.99°, 29.40°, 30.85°.
  • the XRPD pattern of the above crystal form A is shown in FIG. 1 .
  • the differential scanning calorimetry curve of the above crystal form A has an endothermic peak at 188.5°C ⁇ 3.0°C.
  • the DSC spectrum of the above crystal form A is shown in FIG. 2 .
  • the weight loss of the thermogravimetric analysis curve of the above crystal form A reaches 1.56% at 150°C ⁇ 3°C.
  • the TGA spectrum of the above crystal form A is shown in FIG. 3 .
  • the present invention also provides a preparation method of formula (II) compound A crystal form, comprising:
  • the alcoholic solvent is selected from isopropanol, ethanol and methanol.
  • the present invention also provides the application of the compound of formula (II) or its crystal form A or the crystal form prepared according to the above method in the preparation of a medicament for treating non-alcoholic steatohepatitis (NASH).
  • NASH non-alcoholic steatohepatitis
  • the betaine salt form of the present invention has better stability (including moisture absorption stability and storage stability), for example, it is stable for one month at 40°C/75RH% and no by-products are found;
  • the betaine salt type compound also has better crystallinity, higher purity and the like.
  • the compound of the invention has a stable crystal form and good druggability.
  • the intermediate compound of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by its combination with other chemical synthesis methods, and the methods described by those skilled in the art. Known equivalents, preferred embodiments include, but are not limited to, the examples of the present invention.
  • the structure of the compounds of the present invention can be confirmed by conventional methods known to those skilled in the art. If the present invention involves the absolute configuration of the compound, the absolute configuration can be confirmed by conventional technical means in the art. For example, in single crystal X-ray diffraction (SXRD), the cultured single crystal is collected with a Bruker D8 venture diffractometer to collect diffraction intensity data, the light source is CuK ⁇ radiation, and the scanning method is: After scanning and collecting relevant data, the absolute configuration can be confirmed by further analyzing the crystal structure by direct method (Shelxs97).
  • SXRD single crystal X-ray diffraction
  • rt stands for room temperature
  • THF tetrahydrofuran
  • NMP N-methylpyrrolidone
  • MeSO 3 H stands for methanesulfonic acid
  • DME ethylene glycol dimethyl ether
  • DCM stands for dichloromethane
  • Xphos stands for 2-bicyclohexylphosphine-2'4'6'-triisopropylbiphenyl
  • EtOAc stands for ethyl acetate
  • MeOH stands for methanol
  • acetone stands for acetone
  • 2-Me-THF 2-methyltetrahydrofuran
  • IPA stands for isopropyl alcohol
  • DAST stands for diethylaminosulfur trifluoride.
  • Test method About 10-20 mg of sample is used for XRPD detection.
  • Phototube voltage 40kV
  • phototube current 40mA
  • the present invention 's differential thermal analysis (Differential Scanning Calorimeter, DSC) method
  • Test method Take a sample ( ⁇ 1mg) and place it in a DSC aluminum pot for testing. Under the condition of 50mL/min N 2 , heat the sample from 30°C (room temperature) to 300°C (or 350°C) at a heating rate of 10°C/min. °C).
  • Thermogravimetric Analysis (Thermal Gravimetric Analyzer, TGA) method of the present invention
  • Test method Take a sample (2 ⁇ 5mg) and place it in a TGA platinum pot for testing. Under the condition of 25mL/min N 2 , at a heating rate of 10°C/min, heat the sample from room temperature to 350°C or lose 20% of its weight.
  • Test conditions Take a sample (10-15 mg) and place it in a DVS sample tray for testing.
  • ⁇ W% represents the moisture absorption weight gain of the test product at 25 ⁇ 1°C and 80 ⁇ 2%RH.
  • Fig. 1 is the XRPD spectrogram of the Cu-K ⁇ radiation of (II) Compound A crystal form
  • Fig. 2 is the DSC spectrogram of (II) Compound A crystal form
  • Fig. 3 is the TGA spectrogram of (II) Compound A crystal form
  • Fig. 4 is the DVS spectrogram of (II) compound A crystal form.
  • Embodiment 1 the preparation of formula (I) compound
  • A-1_1 50 g, 264.49 mmol
  • NaOMe 100 g, 1.85 mol
  • MeOH 500 mL
  • the reaction solution was directly spin-dried, water (500 mL) was added, and extracted with EtOAc (400 mL), and the organic phase was spin-dried to obtain A-1_2.
  • A-1_2 (90g, 499.44mmol), CHCl 3 (1000mL) was added to a 3000mL three-necked flask, m-chloroperoxybenzoic acid (287.23g, 1.41mmol, 85% purity) was added, and the reaction was carried out at 30°C under nitrogen protection Stirring was continued for 12 hours.
  • reaction solution was filtered, and the filter cake was washed with dichloromethane (500mL), and the filtrate was slowly added to a saturated sodium sulfite solution (500g of sodium sulfite was made into about 2.5L), stirred for one hour to quench the oxidant, separated, and washed with 1000mL of dichloromethane Wash the water phase, combine the organic phase, spin dry, add 1000mL methyl tert-butyl ether, and wash the organic phase with saturated sodium carbonate solution (500mL ⁇ 3), combine the water phase, and then wash the water phase with 500ml methyl tert-butyl ether , (sodium carbonate solution) aqueous phases were combined, extracted with chloroform (2L ⁇ 4), chloroform organic phases were combined, and spin-dried to obtain A-1_3.
  • dichloromethane 500g of sodium sulfite was made into about 2.5L
  • A-1_3 (59g, 300.71mmol) was added to a 1000mL single-necked flask, acetic anhydride (250mL) was added, and the reaction was stirred at 80°C for 5 hours under nitrogen protection.
  • the reaction solution was slowly added to water (500 mL), extracted with ethyl acetate (300 mL ⁇ 2), and the organic phase was directly spin-dried to obtain a crude product.
  • the crude product was purified by flash silica gel column (ISCO cake, 330g SepaFlash silica gel column, eluent: 0-10% EtOAc/PE, flow rate 100mL/min) to obtain A-1_4.
  • A-1_4 40g, 167.9mmol
  • THF 400mL
  • H 2 O 100mL
  • LiOH.H 2 O 14g, 335.8mmol
  • the reaction solution was directly spin-dried.
  • the crude product was purified by flash silica gel column (ISCO 330g SepaFlash silica gel column, eluent: 0-20% EtOAc/PE, flow rate 35mL/min) to obtain A-1_5.
  • A-1_5 150g, 764.52mmol
  • DCM 1,500mL
  • Dess-Martin oxidant 660g, 1.56mol
  • the reaction solution was directly filtered, and the filter cake was washed with ethyl acetate (200 mL), and the filtrate was directly spin-dried.
  • Purify with a flash silica gel column (ISCO cake, 330g SepaFlash flash silica gel column, eluent: 0-10% EtOAc/PE, flow rate 100mL/min) to obtain A-1_6.
  • 1 H NMR 400 MHz, CDCl 3
  • A-1_6 (50g, 257.48mmol), DCM (500mL) was added to a 1000mL single-necked flask, DAST (122g, 756.88mmol, 100mL) was added, and the reaction was stirred at 30°C for 20 hours under nitrogen protection.
  • the reaction solution was slowly added to ice water (2000 mL) to quench, and the filter cake was washed with dichloromethane (2000 mL), and the filtrate was directly spin-dried.
  • Purify with a flash silica gel column (ISCO cake, 330g SepaFlash silica gel column, eluent: 0-10% EtOAc/PE, flow rate 100 mL/min) to obtain A-1_7.
  • A-1_7 (50g, 231.28mmol), THF (100mL) were added to a 1000mL single-necked flask, concentrated hydrochloric acid (500mL) was added, and the reaction was stirred at 80°C for 12 hours under nitrogen protection. The reaction solution was slowly cooled to room temperature, the turbid solution was filtered, and the filter cake was washed with ethyl acetate (50 mL) to obtain A-1_8.
  • A-1_8 (34g, 180.72mmol) was added to a 1000mL single-necked flask, POCl 3 (206mL) was added, and the reaction was stirred at 120°C for 12 hours under nitrogen protection.
  • the reaction solution was spin-dried, diluted with dichloromethane (500 mL) and slowly added to water (1500 mL) to quench, and then the organic phase was extracted with dichloromethane (1000 mL ⁇ 3) and spin-dried to obtain A-1.
  • Embodiment 2 Preparation of formula (II) compound A crystal form
  • Embodiment 3 Research on the hygroscopicity of formula (II) compound A crystal form
  • the hygroscopic weight gain of compound A crystal form of formula (II) at 25° C. and 80% RH is 0.29%, which is slightly hygroscopic.
  • Preparation buffer containing 50mM hydroxyethylpiperazine ethanesulfonic acid (Hepes), 140mM KCl, 3.5mM MgCl2, 0.01% bovine serum albumin (BSA), pH value is 7.4.
  • the compound starts from a concentration of 500 ⁇ M, and is diluted 3 times to 9 concentration points.
  • the final concentration of the compound in the reaction system starts from 10 ⁇ M, and the final concentration of dimethyl sulfoxide (DMSO) is 2%.
  • DMSO dimethyl sulfoxide
  • the first well of each row is the positive control of the compound, that is, add the same volume of buffer to replace the compound and fructokinase; the last well is the negative control of the compound, that is, add the same volume of buffer to replace the compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Disclosed are a salt form and a crystal form of a spiro compound and a preparation method therefor. Further comprised is the use of the salt form and the crystal form in the preparation of a drug for treating related diseases.

Description

一种螺环化合物的盐型、晶型及其制备方法Salt form, crystal form and preparation method of a kind of spiro compound 技术领域technical field
本发明公开了一种螺环化合物的盐型、晶型及其制备方法，还包括所述盐型和晶型及在相关疾病的药物中的应用。The invention discloses a salt form, a crystal form of a spiro compound and a preparation method thereof, and also includes the application of the salt form and the crystal form and medicines for related diseases.
背景技术Background technique
非酒精性脂肪性肝病(NAFLD)在发达国家和地区患病率高，约15％～40％，其中10～20％NAFLD患者会发展为非酒精性脂肪性肝炎(NASH)，估计世界范围NASH的发病率在5～7％，在糖尿病人群中发病率会提高至22％，值得注意的是，NASH患者中约有15～25％会发展成为肝硬化。NASH目前是美国肝移植的第二大病因，预计在2020年将会成为美国肝移植的第一大病因，目前尚无任何获准的治疗NASH药物。The prevalence of nonalcoholic fatty liver disease (NAFLD) is high in developed countries and regions, about 15% to 40%, and 10% to 20% of NAFLD patients will develop nonalcoholic steatohepatitis (NASH). It is estimated that NASH worldwide The incidence rate of NASH is 5-7%, and the incidence rate will increase to 22% in people with diabetes. It is worth noting that about 15-25% of NASH patients will develop into liver cirrhosis. NASH is currently the second leading cause of liver transplantation in the United States, and is expected to become the first leading cause of liver transplantation in the United States in 2020. There are currently no approved drugs for the treatment of NASH.
最近的研究发现高果糖饮食是造成NASH的重要原因。果糖进入肝脏后会迅速被果糖激酶Ketohexokinase(KHK)磷酸化成为果糖-1-磷酸。果糖-1-磷酸进入细胞后进一步产生的代谢产物会成为糖异生和脂肪从头合成(DNL)的底物，导致肝脏脂质合成增加及胰岛素抵抗从而增加氧化应激和炎症，加快NAFLD和NASH的发病过程。KHK是果糖代谢为果糖-1-磷酸的限速酶，是调节果糖代谢的重要靶点。因此抑制KHK可以有效的抑制果糖代谢及其造成的脂质堆积、氧化应激、炎症和胰岛素抵抗，从而用于NASH治疗。Recent studies have found that a high-fructose diet is an important cause of NASH. After entering the liver, fructose is quickly phosphorylated by fructokinase Ketohexokinase (KHK) into fructose-1-phosphate. After fructose-1-phosphate enters cells, further metabolites will become substrates for gluconeogenesis and de novo fat synthesis (DNL), leading to increased liver lipid synthesis and insulin resistance, thereby increasing oxidative stress and inflammation, and accelerating NAFLD and NASH disease process. KHK is the rate-limiting enzyme for the metabolism of fructose to fructose-1-phosphate and is an important target for regulating fructose metabolism. Therefore, inhibiting KHK can effectively inhibit fructose metabolism and its resulting lipid accumulation, oxidative stress, inflammation and insulin resistance, and thus be used for the treatment of NASH.
发明内容Contents of the invention
本发明提供式(II)化合物，The present invention provides a compound of formula (II),
Figure PCTCN2022099375-appb-000001
Figure PCTCN2022099375-appb-000001
本发明还提供式(II)化合物的A晶型，其特征在于其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：9.73±0.20°，11.22±0.20°，12.66±0.20°，18.38±0.20°。The present invention also provides crystal form A of the compound of formula (II), which is characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.73±0.20°, 11.22±0.20°, 12.66±0.20°, 18.38± 0.20°.
在本发明的一些方案中，上述A晶型的X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：6.94±0.20°，9.73±0.20°，11.22±0.20°，12.66±0.20°，15.63±0.20°，16.62±0.20°，18.38±0.20°，20.81±0.20°。In some solutions of the present invention, the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2θ angles: 6.94±0.20°, 9.73±0.20°, 11.22±0.20°, 12.66±0.20°, 15.63± 0.20°, 16.62±0.20°, 18.38±0.20°, 20.81±0.20°.
在本发明的一些方案中，上述A晶型的X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：6.46±0.20°，6.94±0.20°，9.73±0.20°，11.22±0.20°，12.66±0.20°，15.63±0.20°，16.62±0.20°，18.38±0.20°，19.64±0.20°，20.81±0.20°，22.51±0.20°，24.58±0.20°。In some solutions of the present invention, the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2θ angles: 6.46±0.20°, 6.94±0.20°, 9.73±0.20°, 11.22±0.20°, 12.66± 0.20°, 15.63±0.20°, 16.62±0.20°, 18.38±0.20°, 19.64±0.20°, 20.81±0.20°, 22.51±0.20°, 24.58±0.20°.
在本发明的一些方案中，上述A晶型的X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：4.47±0.20°，6.46±0.20°，6.94±0.20°，9.73±0.20°，11.22±0.20°，12.25±0.20°，12.66±0.20°，15.63±0.20°，16.62±0.20°，17.83±0.20°，18.38±0.20°，19.64±0.20°，20.81±0.20°，22.51±0.20°，23.59±0.20°，24.58±0.20°。In some solutions of the present invention, the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2θ angles: 4.47±0.20°, 6.46±0.20°, 6.94±0.20°, 9.73±0.20°, 11.22± 0.20°, 12.25±0.20°, 12.66±0.20°, 15.63±0.20°, 16.62±0.20°, 17.83±0.20°, 18.38±0.20°, 19.64±0.20°, 20.81±0.20°, 22.51±0.20°, 23.59± 0.20°, 24.58±0.20°.
在本发明的一些方案中，上述A晶型的X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：4.47°，6.46°，6.94°，9.73°，10.18°，11.22°，12.25°，12.66°，13.30°，14.30°，15.63°，16.62°，17.27°，17.83°，18.38°，18.67°，19.37°，19.64°，20.06°，20.41°，20.81°，21.72°，22.51°，23.59°，24.58°，25.11°，26.44°，27.41°，27.99°，29.40°，30.85°。In some solutions of the present invention, the X-ray powder diffraction pattern of the above crystal form A has characteristic diffraction peaks at the following 2θ angles: 4.47°, 6.46°, 6.94°, 9.73°, 10.18°, 11.22°, 12.25°, 12.66 °, 13.30°, 14.30°, 15.63°, 16.62°, 17.27°, 17.83°, 18.38°, 18.67°, 19.37°, 19.64°, 20.06°, 20.41°, 20.81°, 21.72°, 22.51°, 23.59°, 24.58°, 25.11°, 26.44°, 27.41°, 27.99°, 29.40°, 30.85°.
在本发明的一些方案中，上述A晶型的XRPD图谱如图1所示。In some solutions of the present invention, the XRPD pattern of the above crystal form A is shown in FIG. 1 .
本发明的一些方案中，上述A晶型的XRPD图谱解析数据如表1所示：In some solutions of the present invention, the XRPD spectrum analysis data of the above crystal form A are shown in Table 1:
表1Table 1
Figure PCTCN2022099375-appb-000002
Figure PCTCN2022099375-appb-000002
在本发明的一些方案中，上述A晶型的差示扫描量热曲线在188.5℃±3.0℃处有一个吸热峰的峰值。In some solutions of the present invention, the differential scanning calorimetry curve of the above crystal form A has an endothermic peak at 188.5°C±3.0°C.
在本发明的一些方案中，上述A晶型的DSC图谱如图2所示。In some solutions of the present invention, the DSC spectrum of the above crystal form A is shown in FIG. 2 .
在本发明的一些方案中，上述A晶型的热重分析曲线在150℃±3℃时失重达1.56％。In some solutions of the present invention, the weight loss of the thermogravimetric analysis curve of the above crystal form A reaches 1.56% at 150°C±3°C.
在本发明的一些方案中，上述A晶型的TGA图谱如图3所示。In some solutions of the present invention, the TGA spectrum of the above crystal form A is shown in FIG. 3 .
本发明还提供式(II)化合物A晶型的制备方法，包括：The present invention also provides a preparation method of formula (II) compound A crystal form, comprising:
Figure PCTCN2022099375-appb-000003
Figure PCTCN2022099375-appb-000003
(a)将式(I)化合物加入醇类溶剂中溶解；(a) adding the compound of formula (I) to dissolve in an alcoholic solvent;
(b)在搅拌下缓慢加入甜菜碱和醇类溶剂的混合溶液；(b) slowly add the mixed solution of betaine and alcoholic solvent under stirring;
(c)20～30℃下搅拌8～16小时；(c) stirring at 20 to 30°C for 8 to 16 hours;
(d)过滤后干燥8～16小时；(d) drying for 8 to 16 hours after filtration;
其中，所述醇类溶剂选自异丙醇、乙醇和甲醇。Wherein, the alcoholic solvent is selected from isopropanol, ethanol and methanol.
本发明还提供式(Ⅱ)化合物或其A晶型或根据上述方法制备得到的晶型在制备治疗非酒精性脂肪性肝炎(NASH)的药物中的应用。The present invention also provides the application of the compound of formula (II) or its crystal form A or the crystal form prepared according to the above method in the preparation of a medicament for treating non-alcoholic steatohepatitis (NASH).
有益效果Beneficial effect
本发明所述的甜菜碱盐型相对于其他盐型，具有更好的稳定性(包括吸湿稳定性，储存稳定性)，例如在40℃/75RH％条件下一个月稳定且未发现副产物；甜菜碱盐型化合物也具有更好的结晶性，更高的纯度等。同时，本发明所述化合物晶型稳定，成药性好。Compared with other salt forms, the betaine salt form of the present invention has better stability (including moisture absorption stability and storage stability), for example, it is stable for one month at 40°C/75RH% and no by-products are found; The betaine salt type compound also has better crystallinity, higher purity and the like. At the same time, the compound of the invention has a stable crystal form and good druggability.
定义和说明Definition and Description
除非另有说明，本文所用的下列术语和短语旨在含有下列含义。一个特定的短语或术语在没有特别定义的情况下不应该被认为是不确定的或不清楚的，而应该按照普通的含义去理解。当本文出现商品名时，旨在指代其对应的商品或其活性成分。Unless otherwise stated, the following terms and phrases used herein are intended to have the following meanings. A specific phrase or term should not be considered indeterminate or unclear if it is not specifically defined, but should be understood according to its ordinary meaning. When a trade name appears herein, it is intended to refer to its corresponding trade name or its active ingredient.
本发明的中间体化合物可以通过本领域技术人员所熟知的多种合成方法来制备，包括下面列举的具体实施方式、其与其他化学合成方法的结合所形成的实施方式以及本领域技术上人员所熟知的等同替换方式，优选的实施方式包括但不限于本发明的实施例。The intermediate compound of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by its combination with other chemical synthesis methods, and the methods described by those skilled in the art. Known equivalents, preferred embodiments include, but are not limited to, the examples of the present invention.
本发明具体实施方式的化学反应是在合适的溶剂中完成的，所述的溶剂须适合于本发明的化学变化及其所需的试剂和物料。为了获得本发明的化合物，有时需要本领域技术人员在已有实施方式的基础上对合成步骤或者反应流程进行修改或选择。The chemical reactions of the specific embodiments of the present invention are completed in a suitable solvent, and the solvent must be suitable for the chemical changes of the present invention and the required reagents and materials. In order to obtain the compounds of the present invention, it is sometimes necessary for those skilled in the art to modify or select synthetic steps or reaction schemes on the basis of existing embodiments.
本发明的化合物可以通过本领域技术人员所熟知的常规方法来确认结构，如果本发明涉及化合物的绝对构型，则该绝对构型可以通过本领域常规技术手段予以确证。例如单晶X射线衍射法(SXRD)，把培养出的单晶用Bruker D8 venture衍射仪收集衍射强度数据，光源为CuKα辐射，扫描方式：
Figure PCTCN2022099375-appb-000004
扫描，收集相关数据后，进一步采用直接法(Shelxs97)解析晶体结构，便可以确证绝对构型。 The structure of the compounds of the present invention can be confirmed by conventional methods known to those skilled in the art. If the present invention involves the absolute configuration of the compound, the absolute configuration can be confirmed by conventional technical means in the art. For example, in single crystal X-ray diffraction (SXRD), the cultured single crystal is collected with a Bruker D8 venture diffractometer to collect diffraction intensity data, the light source is CuKα radiation, and the scanning method is:
Figure PCTCN2022099375-appb-000004
After scanning and collecting relevant data, the absolute configuration can be confirmed by further analyzing the crystal structure by direct method (Shelxs97).
下面会通过实施例具体描述本发明，这些实施例并不意味着对本发明的任何限制。The present invention will be specifically described by examples below, and these examples do not imply any limitation to the present invention.
本发明所使用的所有溶剂是市售的，无需进一步纯化即可使用。All solvents used in the present invention are commercially available and used without further purification.
本发明采用下述缩略词：r.t.代表室温；THF代表四氢呋喃；NMP代表N-甲基吡咯烷酮；MeSO 3H代表甲烷磺酸；DME代表乙二醇二甲醚；DCM代表二氯甲烷；Xphos代表2-双环己基膦-2’4’6’-三异丙基联苯；EtOAc代表乙酸乙酯；MeOH代表甲醇；acetone代表丙酮；2-Me-THF代表2-甲基四氢呋喃；IPA代表异丙醇；DAST代表二乙胺基三氟化硫。 The following abbreviations are used in the present invention: rt stands for room temperature; THF stands for tetrahydrofuran; NMP stands for N-methylpyrrolidone; MeSO 3 H stands for methanesulfonic acid; DME stands for ethylene glycol dimethyl ether; DCM stands for dichloromethane; Xphos stands for 2-bicyclohexylphosphine-2'4'6'-triisopropylbiphenyl; EtOAc stands for ethyl acetate; MeOH stands for methanol; acetone stands for acetone; 2-Me-THF stands for 2-methyltetrahydrofuran; IPA stands for isopropyl alcohol; DAST stands for diethylaminosulfur trifluoride.
化合物经手工或者
Figure PCTCN2022099375-appb-000005
软件命名，市售化合物采用供应商目录名称。 Compounds were manually or
Figure PCTCN2022099375-appb-000005
The software is named, and the commercially available compounds adopt the supplier catalog name.
本发明粉末X-射线衍射(X-ray powder diffractometer,XRPD)方法Powder X-ray diffraction (X-ray powder diffractometer, XRPD) method of the present invention
仪器型号：布鲁克D8 advance X-射线衍射仪Instrument model: Bruker D8 advance X-ray diffractometer
测试方法：大约10～20mg样品用于XRPD检测。Test method: About 10-20 mg of sample is used for XRPD detection.
详细的XRPD参数如下：The detailed XRPD parameters are as follows:
光管：Cu,kα,
Figure PCTCN2022099375-appb-000006
Light pipe: Cu, kα,
Figure PCTCN2022099375-appb-000006
光管电压：40kV，光管电流：40mAPhototube voltage: 40kV, phototube current: 40mA
发散狭缝：0.60mmDivergence slit: 0.60mm
探测器狭缝：10.50mmDetector slit: 10.50mm
防散射狭缝：7.10mmAnti-scatter slit: 7.10mm
扫描范围：4-40degScanning range: 4-40deg
步径：0.02degStep: 0.02deg
步长：0.12秒Step size: 0.12 seconds
样品盘转速：15rpmSample disk speed: 15rpm
本发明差热分析(Differential Scanning Calorimeter,DSC)方法The present invention's differential thermal analysis (Differential Scanning Calorimeter, DSC) method
仪器型号：TA Q2000差示扫描量热仪Instrument Model: TA Q2000 Differential Scanning Calorimeter
测试方法：取样品(～1mg)置于DSC铝锅内进行测试，在50mL/min N 2条件下，以10℃/min的升温速率，加热样品从30℃(室温)到300℃(或350℃)。 Test method: Take a sample (~1mg) and place it in a DSC aluminum pot for testing. Under the condition of 50mL/min N 2 , heat the sample from 30°C (room temperature) to 300°C (or 350°C) at a heating rate of 10°C/min. ℃).
本发明热重分析(Thermal Gravimetric Analyzer,TGA)方法Thermogravimetric Analysis (Thermal Gravimetric Analyzer, TGA) method of the present invention
仪器型号：TA Q5000IR热重分析仪Instrument Model: TA Q5000IR Thermogravimetric Analyzer
测试方法：取样品(2～5mg)置于TGA铂金锅内进行测试，在25mL/min N 2条件下，以10℃/min的升温速率，加热样品从室温到350℃或失重20％。 Test method: Take a sample (2~5mg) and place it in a TGA platinum pot for testing. Under the condition of 25mL/min N 2 , at a heating rate of 10°C/min, heat the sample from room temperature to 350°C or lose 20% of its weight.
本发明动态蒸汽吸附分析(Dynamic Vapor Sorption,DVS)方法Dynamic vapor adsorption analysis (Dynamic Vapor Sorption, DVS) method of the present invention
仪器型号：SMS DVS Advantage动态蒸汽吸附仪Instrument model: SMS DVS Advantage dynamic vapor adsorption instrument
测试条件：取样品(10～15mg)置于DVS样品盘内进行测试。Test conditions: Take a sample (10-15 mg) and place it in a DVS sample tray for testing.
详细的DVS参数如下：The detailed DVS parameters are as follows:
温度：25℃Temperature: 25°C
平衡：dm/dt＝0.01％/min(最短：10min，最长：180min)Balance: dm/dt=0.01%/min (shortest: 10min, longest: 180min)
干燥：0％RH下干燥120minDrying: 120min at 0% RH
RH(％)测试梯级：10％RH(%) test rung: 10%
RH(％)测试梯级范围：0％-90％-0％RH (%) test step range: 0%-90%-0%
引湿性评价分类如下：The classification of hygroscopicity evaluation is as follows:
吸湿性分类Hygroscopicity Classification ΔW％ΔW%
潮解deliquescence 吸收足量水分形成液体Absorb enough water to form a liquid
极具吸湿性Very hygroscopic ΔW％≥15％ΔW%≥15%
有吸湿性Hygroscopic 15％>ΔW％≥2％15%>ΔW%≥2%
略有吸湿性slightly hygroscopic 2％>ΔW％≥0.2％2%>ΔW%≥0.2%
无或几乎无吸湿性No or almost no hygroscopicity ΔW％<0.2％ΔW%<0.2%
注：ΔW％表示受试品在25±1℃和80±2％RH下的吸湿增重。Note: ΔW% represents the moisture absorption weight gain of the test product at 25±1°C and 80±2%RH.
附图说明Description of drawings
图1为(II)化合物A晶型的Cu-Kα辐射的XRPD谱图；Fig. 1 is the XRPD spectrogram of the Cu-Kα radiation of (II) Compound A crystal form;
图2为(II)化合物A晶型的DSC谱图；Fig. 2 is the DSC spectrogram of (II) Compound A crystal form;
图3为(II)化合物A晶型的TGA谱图；Fig. 3 is the TGA spectrogram of (II) Compound A crystal form;
图4为(II)化合物A晶型的DVS谱图。Fig. 4 is the DVS spectrogram of (II) compound A crystal form.
具体实施方式detailed description
为了更好的理解本发明的内容，下面结合具体实施例来做进一步的说明，但具体的实施方式并不是对本发明的内容所做的限制。In order to better understand the content of the present invention, the following will be further described in conjunction with specific examples, but the specific implementation is not a limitation to the content of the present invention.
实施例1：式(I)化合物的制备Embodiment 1: the preparation of formula (I) compound
Figure PCTCN2022099375-appb-000007
Figure PCTCN2022099375-appb-000007
合成路线：synthetic route:
Figure PCTCN2022099375-appb-000008
Figure PCTCN2022099375-appb-000008
步骤1：化合物A-1_2的合成Step 1: Synthesis of Compound A-1_2
向将A-1_1(50g,264.49mmol)，NaOMe(100g,1.85mol)溶于MeOH(500mL)中，在氮气保护下反应在80℃下搅拌12小时。LC-MS显示原料信号消失，有产物信号生成，TLC(石油醚：乙酸乙酯＝3:1)显示有新点生成。将反应液直接旋干，加入水(500mL)，并用EtOAc(400mL)萃取，将有机相旋干，得到A-1_2。A-1_1 (50 g, 264.49 mmol), NaOMe (100 g, 1.85 mol) were dissolved in MeOH (500 mL), and the reaction was stirred at 80° C. for 12 hours under nitrogen protection. LC-MS showed that the raw material signal disappeared, and a product signal was generated, and TLC (petroleum ether: ethyl acetate = 3:1) showed that new spots were generated. The reaction solution was directly spin-dried, water (500 mL) was added, and extracted with EtOAc (400 mL), and the organic phase was spin-dried to obtain A-1_2.
步骤2：化合物A-1_3的合成Step 2: Synthesis of Compound A-1_3
将A-1_2(90g,499.44mmol)，CHCl 3(1000mL)加入到3000mL三口瓶中，加入间氯过氧苯甲酸(287.23g,1.41mmol,85％纯度)，在氮气保护下反应在30℃下搅拌12小时。LCMS显示原料信号未消失，有产物信号生成，TLC(二氯甲烷：甲醇＝10:1)显示有新点生成。将反应液过滤，并用二氯甲烷(500mL)洗涤滤饼，滤液慢慢加入到饱和亚硫酸钠溶液中(500g亚硫酸钠配成约2.5L)，搅拌一小时淬灭氧化剂，分液，用1000mL二氯甲烷洗涤水相，合并有机相，旋干，加入1000mL甲基叔丁基醚，并用饱和碳酸钠溶液(500mL×3)洗涤有机相，水相合并，再用500ml甲基叔丁基醚洗涤水相，(碳酸钠溶液)水相合并，用氯仿(2L×4)萃取，氯仿有机相合并，旋干，得到A-1_3。 1H NMR(400MHz,CDCl 3)δ＝4.24-4.11(m,3H)，4.06-3.95(m,3H)，3.20(t,J＝7.8Hz,2H)，2.86(t,J＝7.7Hz,2H)，2.28-2.15(m,2H)。 A-1_2 (90g, 499.44mmol), CHCl 3 (1000mL) was added to a 3000mL three-necked flask, m-chloroperoxybenzoic acid (287.23g, 1.41mmol, 85% purity) was added, and the reaction was carried out at 30°C under nitrogen protection Stirring was continued for 12 hours. LCMS showed that the raw material signal did not disappear, but a product signal was generated, and TLC (dichloromethane:methanol=10:1) showed that new spots were generated. The reaction solution was filtered, and the filter cake was washed with dichloromethane (500mL), and the filtrate was slowly added to a saturated sodium sulfite solution (500g of sodium sulfite was made into about 2.5L), stirred for one hour to quench the oxidant, separated, and washed with 1000mL of dichloromethane Wash the water phase, combine the organic phase, spin dry, add 1000mL methyl tert-butyl ether, and wash the organic phase with saturated sodium carbonate solution (500mL×3), combine the water phase, and then wash the water phase with 500ml methyl tert-butyl ether , (sodium carbonate solution) aqueous phases were combined, extracted with chloroform (2L×4), chloroform organic phases were combined, and spin-dried to obtain A-1_3. 1 H NMR (400MHz, CDCl 3 ) δ=4.24-4.11(m,3H), 4.06-3.95(m,3H), 3.20(t,J=7.8Hz,2H), 2.86(t,J=7.7Hz, 2H), 2.28-2.15 (m, 2H).
步骤3：化合物A-1_4的合成Step 3: Synthesis of Compound A-1_4
将A-1_3(59g,300.71mmol)加入到1000mL单口瓶中，加入乙酸酐(250mL)，在氮气保护下反应在80℃下搅拌5小时。将反应液慢慢加入到水(500mL)中，并用乙酸乙酯(300mL×2)萃取，将有机相直接旋干，得到粗品。粗品用快速硅胶柱(ISCO饼，330g SepaFlash硅胶柱，洗脱剂：0～10％EtOAc/PE，流速100mL/min)纯化，得到A-1_4。 1H NMR(400MHz,CDCl 3)δ＝6.12-5.90(m,1H),4.02(d,J＝7.0Hz,6H),2.95-2.82(m,1H),2.78-2.57(m,2H),2.14(s,3H),2.08-1.96(m,1H)。 A-1_3 (59g, 300.71mmol) was added to a 1000mL single-necked flask, acetic anhydride (250mL) was added, and the reaction was stirred at 80°C for 5 hours under nitrogen protection. The reaction solution was slowly added to water (500 mL), extracted with ethyl acetate (300 mL×2), and the organic phase was directly spin-dried to obtain a crude product. The crude product was purified by flash silica gel column (ISCO cake, 330g SepaFlash silica gel column, eluent: 0-10% EtOAc/PE, flow rate 100mL/min) to obtain A-1_4. 1 H NMR (400MHz, CDCl 3 )δ=6.12-5.90(m,1H),4.02(d,J=7.0Hz,6H),2.95-2.82(m,1H),2.78-2.57(m,2H), 2.14(s,3H),2.08-1.96(m,1H).
步骤4：化合物A-1_5的合成Step 4: Synthesis of Compound A-1_5
将A-1_4(40g,167.9mmol)，THF(400mL)/H 2O(100mL)加入到1000mL单口瓶中，加入LiOH.H 2O(14g,335.8mmol)，在氮气保护下反应在20℃下搅拌12小时。将反应液直接旋干。粗品用快速硅胶柱(ISCO 330g SepaFlash硅胶柱,洗脱剂：0～20％EtOAc/PE，流速35mL/min)纯化，得到A-1_5。 1H NMR(400MHz,CDCl 3)δ＝5.10(t,J＝7.0Hz,1H),4.10-3.96(m,6H),2.88(ddd,J＝2.8,8.9,15.4Hz,1H),2.70-2.48(m,2H),2.12-1.94(m,1H)。 Add A-1_4 (40g, 167.9mmol), THF (400mL)/H 2 O (100mL) into a 1000mL one-necked flask, add LiOH.H 2 O (14g, 335.8mmol), and react at 20°C under nitrogen protection Stirring was continued for 12 hours. The reaction solution was directly spin-dried. The crude product was purified by flash silica gel column (ISCO 330g SepaFlash silica gel column, eluent: 0-20% EtOAc/PE, flow rate 35mL/min) to obtain A-1_5. 1 H NMR (400MHz, CDCl 3 ) δ=5.10(t, J=7.0Hz, 1H), 4.10-3.96(m, 6H), 2.88(ddd, J=2.8, 8.9, 15.4Hz, 1H), 2.70- 2.48(m,2H),2.12-1.94(m,1H).
步骤5：化合物A-1_6的合成Step 5: Synthesis of Compound A-1_6
将A-1_5(150g,764.52mmol)，DCM(1500mL)加入到5L三口瓶中，加入戴斯－马丁氧化剂(660g,1.56mol)，在氮气保护下反应在20℃下搅拌12小时。将反应液直接过滤，并用乙酸乙酯(200mL)洗涤滤饼，将滤液直接旋干。用快速硅胶柱(ISCO饼，330g SepaFlash用快硅胶柱,洗脱剂：0～10％EtOAc/PE，流速100mL/min)纯化，得到A-1_6。 1H NMR(400MHz,CDCl 3)δ＝4.02(d,J＝8.3Hz,6H),2.92-2.82(m,2H),2.71-2.62(m,2H)。 Add A-1_5 (150g, 764.52mmol), DCM (1500mL) into a 5L three-necked flask, add Dess-Martin oxidant (660g, 1.56mol), react under nitrogen protection and stir at 20°C for 12 hours. The reaction solution was directly filtered, and the filter cake was washed with ethyl acetate (200 mL), and the filtrate was directly spin-dried. Purify with a flash silica gel column (ISCO cake, 330g SepaFlash flash silica gel column, eluent: 0-10% EtOAc/PE, flow rate 100mL/min) to obtain A-1_6. 1 H NMR (400 MHz, CDCl 3 ) δ = 4.02 (d, J = 8.3 Hz, 6H), 2.92-2.82 (m, 2H), 2.71-2.62 (m, 2H).
步骤6：化合物A-1_7的合成Step 6: Synthesis of Compound A-1_7
将A-1_6(50g,257.48mmol)，DCM(500mL)加入到1000mL单口瓶中，加入DAST(122g,756.88mmol,100mL)，在氮气保护下反应在30℃下搅拌20小时。将反应液慢慢加入到冰水(2000mL)淬灭，并用二氯甲烷(2000mL)洗涤滤饼，将滤液直接旋干。用快速硅胶柱(ISCO饼，330g SepaFlash硅胶柱,洗脱剂：0～10％EtOAc/PE，流速100 mL/min)纯化，得到A-1_7。 1H NMR(400MHz,CDCl 3)δ＝3.98(d,J＝5.1Hz,6H),2.83-2.70(m,2H),2.62-2.41(m,2H)。 A-1_6 (50g, 257.48mmol), DCM (500mL) was added to a 1000mL single-necked flask, DAST (122g, 756.88mmol, 100mL) was added, and the reaction was stirred at 30°C for 20 hours under nitrogen protection. The reaction solution was slowly added to ice water (2000 mL) to quench, and the filter cake was washed with dichloromethane (2000 mL), and the filtrate was directly spin-dried. Purify with a flash silica gel column (ISCO cake, 330g SepaFlash silica gel column, eluent: 0-10% EtOAc/PE, flow rate 100 mL/min) to obtain A-1_7. 1 H NMR (400 MHz, CDCl 3 ) δ=3.98 (d, J=5.1 Hz, 6H), 2.83-2.70 (m, 2H), 2.62-2.41 (m, 2H).
步骤7：化合物A-1_8的合成Step 7: Synthesis of Compound A-1_8
将A-1_7(50g,231.28mmol)，THF(100mL)加入到1000mL单口瓶中，加入浓盐酸(500mL)，在氮气保护下反应在80℃下搅拌12小时。将反应液慢慢冷却到室温，将浑浊液过滤，并用乙酸乙酯(50mL)洗涤滤饼，得到A-1_8。 1H NMR(400MHz,CDCl 3)δ＝11.85(br s,1H),11.36-11.12(m,1H),2.61-2.52(m,4H)。 A-1_7 (50g, 231.28mmol), THF (100mL) were added to a 1000mL single-necked flask, concentrated hydrochloric acid (500mL) was added, and the reaction was stirred at 80°C for 12 hours under nitrogen protection. The reaction solution was slowly cooled to room temperature, the turbid solution was filtered, and the filter cake was washed with ethyl acetate (50 mL) to obtain A-1_8. 1 H NMR (400 MHz, CDCl 3 ) δ=11.85 (br s, 1H), 11.36-11.12 (m, 1H), 2.61-2.52 (m, 4H).
步骤8：化合物A-1的合成Step 8: Synthesis of Compound A-1
将A-1_8(34g,180.72mmol)加入到1000mL单口瓶中，加入POCl 3(206mL)，在氮气保护下反应在120℃下搅拌12小时。将反应液旋干，用二氯甲烷(500mL)稀释后慢慢加入到水(1500mL)中淬灭，再用二氯甲烷(1000mL×3)萃取有机相合并旋干，得到A-1。 1H NMR(400MHz,CDCl 3)δ＝3.16-3.01(m,2H),2.85-2.65(m,2H)。 A-1_8 (34g, 180.72mmol) was added to a 1000mL single-necked flask, POCl 3 (206mL) was added, and the reaction was stirred at 120°C for 12 hours under nitrogen protection. The reaction solution was spin-dried, diluted with dichloromethane (500 mL) and slowly added to water (1500 mL) to quench, and then the organic phase was extracted with dichloromethane (1000 mL×3) and spin-dried to obtain A-1. 1 H NMR (400 MHz, CDCl 3 ) δ=3.16-3.01 (m, 2H), 2.85-2.65 (m, 2H).
步骤9：化合物a的合成Step 9: Synthesis of compound a
将化合物B-1(40g,129.28mmol)溶解在DCM(300.0mL)中，降温至0℃缓慢滴加化合物A-1(27g,119.99mmol)的DCM(200.0mL)溶液，然后缓慢滴加DIPEA(46.52g,359.97mmol)。反应在0℃下搅拌3小时。反应结束后旋干移除溶剂得到粗品，粗品经过自动过柱机(100～200目，洗脱剂为PE:EtOAc＝100:1～100:50)过柱纯化得到a。 1H NMR(400MHz,CDCl 3)δ＝4.73-4.23(m,4H),3.72(d,J＝5.5Hz,3H),3.07-2.90(m,2H),2.67-2.48(m,2H),1.93(br d,J＝9.5Hz,1H),1.72-1.51(m,1H),1.75-1.49(m,1H)。 Dissolve compound B-1 (40g, 129.28mmol) in DCM (300.0mL), cool down to 0°C and slowly add compound A-1 (27g, 119.99mmol) in DCM (200.0mL) solution dropwise, then slowly add DIPEA (46.52g, 359.97mmol). The reaction was stirred at 0 °C for 3 hours. After the reaction was completed, the solvent was removed by spinning to obtain a crude product, which was purified through an automatic column passer (100-200 mesh, eluent: PE:EtOAc=100:1-100:50) to obtain a. 1 H NMR (400MHz, CDCl 3 )δ=4.73-4.23(m,4H),3.72(d,J=5.5Hz,3H),3.07-2.90(m,2H),2.67-2.48(m,2H), 1.93 (br d, J=9.5Hz, 1H), 1.72-1.51 (m, 1H), 1.75-1.49 (m, 1H).
步骤10：化合物b的合成Step 10: Synthesis of compound b
将化合物a(35g,106.15mmol)分批加入C-1的盐酸盐(38.65g,127.38mmol)的乙腈(350.0mL)溶液中，然后再加入K 2CO 3(44g,318.44mmol)，反应在80℃下搅拌12小时。反应结束后直接过滤，滤液旋干，得到b。 1H NMR(400MHz,CDCl 3)δ＝4.49-4.35(m,2H),4.33-4.17(m,3H),4.07(dt,J＝5.0,8.8Hz,1H),3.74(s,3H),2.87-2.77(m,2H),2.53-2.36(m,3H),1.97-1.86(m,2H),1.50(d,J＝6.0Hz,3H),1.39(t,J＝5.5Hz,1H),1.32-1.26(m,1H),1.30-1.24(m,1H)。 Compound a (35g, 106.15mmol) was added in batches to a solution of C-1 hydrochloride (38.65g, 127.38mmol) in acetonitrile (350.0mL), and then K 2 CO 3 (44g, 318.44mmol) was added to react Stir at 80°C for 12 hours. After the reaction was completed, it was directly filtered, and the filtrate was spin-dried to obtain b. 1 H NMR (400MHz, CDCl 3 )δ=4.49-4.35(m,2H),4.33-4.17(m,3H),4.07(dt,J=5.0,8.8Hz,1H),3.74(s,3H), 2.87-2.77(m,2H),2.53-2.36(m,3H),1.97-1.86(m,2H),1.50(d,J=6.0Hz,3H),1.39(t,J=5.5Hz,1H) ,1.32-1.26(m,1H),1.30-1.24(m,1H).
步骤11：式I化合物的合成Step 11: Synthesis of Compound of Formula I
将化合物b(36g,98.8mmol)溶解在THF(350.0mL)和H 2O(70.0mL)中，加入一水合氢氧化锂(8.29g,197.59mmol)，反应在20℃下搅拌12小时。反应结束后加入200mL水，加入1N盐酸调pH到5～6。用乙酸乙酯(300mL)萃取。旋蒸移除溶剂，加入25mL MeOH将产物溶解，不溶的无机盐过滤除去。粗品的MeOH溶液经过Prep-HPLC(分离方法：柱型：Phenomenex Luna C8 250*50mm*10μm；流动相：[H 2O(0.225％甲酸)-ACN]；ACN％:5％-35％,10分钟)进行纯化，得到式I化合物。 1H NMR(400MHz,CD 3OD)δppm 4.22-4.50(m,5H),3.86-4.12(m,2H),2.88(br d,J＝3.76Hz,2H),2.32-2.55(m,3H),1.84-2.04(m,2H),1.49(dd,J＝6.02,1.51Hz,3H),1.22-1.37(m,2H).MS(ESI):m/z:351.1[M+1]。 Compound b (36g, 98.8mmol) was dissolved in THF (350.0mL) and H 2 O (70.0mL), lithium hydroxide monohydrate (8.29g, 197.59mmol) was added, and the reaction was stirred at 20°C for 12 hours. After the reaction was completed, 200 mL of water was added, and 1N hydrochloric acid was added to adjust the pH to 5-6. Extract with ethyl acetate (300 mL). The solvent was removed by rotary evaporation, 25 mL of MeOH was added to dissolve the product, and insoluble inorganic salts were removed by filtration. The crude MeOH solution was subjected to Prep-HPLC (separation method: column type: Phenomenex Luna C8 250*50mm*10 μm; mobile phase: [H 2 O (0.225% formic acid)-ACN]; ACN%: 5%-35%, 10 minutes) to purify to obtain the compound of formula I. 1 H NMR (400MHz, CD 3 OD) δppm 4.22-4.50 (m, 5H), 3.86-4.12 (m, 2H), 2.88 (br d, J = 3.76Hz, 2H), 2.32-2.55 (m, 3H) , 1.84-2.04 (m, 2H), 1.49 (dd, J=6.02, 1.51 Hz, 3H), 1.22-1.37 (m, 2H). MS (ESI): m/z: 351.1 [M+1].
实施例2：式(II)化合物A晶型的制备Embodiment 2: Preparation of formula (II) compound A crystal form
Figure PCTCN2022099375-appb-000009
Figure PCTCN2022099375-appb-000009
将20mL异丙醇加入至100mL反应瓶中，室温下将式(I)化合物(2.0g，5.71mmol，1eq)加入反应瓶中，搅拌至溶解澄清，将甜菜碱(702.15mg,5.99mmol,1.05eq)和MeOH(5mL)的溶清液加入到上述反应液中，25℃搅拌过夜。减压抽滤，滤饼用异丙醇(5mL)洗涤，滤饼真空干燥至恒重，得式(II)化合物的A晶型。1H NMR(400MHz,CD 3OD):δ,4.45-4.35(m,5H),4.04-4.02(m,1H),3.93-3.91(m,1H)3.85(s,2H),3.29(s,9H),2.88-2.86(m,2H),2.49–2.40(m,3H),1.95–1.89(m,2H),1.49(d,J＝6.0Hz,3H),1.32(t,J＝4.0Hz,2H). 20mL of isopropanol was added to a 100mL reaction flask, and the compound of formula (I) (2.0g, 5.71mmol, 1eq) was added to the reaction flask at room temperature, stirred until it was dissolved and clarified, and betaine (702.15mg, 5.99mmol, 1.05 The solution of eq) and MeOH (5 mL) was added to the above reaction solution, and stirred overnight at 25°C. Suction filtration under reduced pressure, the filter cake was washed with isopropanol (5 mL), and the filter cake was vacuum-dried to constant weight to obtain the crystal form A of the compound of formula (II). 1H NMR (400MHz, CD 3 OD): δ,4.45-4.35(m,5H),4.04-4.02(m,1H),3.93-3.91(m,1H)3.85(s,2H),3.29(s,9H ),2.88-2.86(m,2H),2.49–2.40(m,3H),1.95–1.89(m,2H),1.49(d,J＝6.0Hz,3H),1.32(t,J＝4.0Hz, 2H).
实施例3：式(II)化合物A晶型的吸湿性研究Embodiment 3: Research on the hygroscopicity of formula (II) compound A crystal form
实验材料：Experimental Materials:
SMS DVS Advantage动态蒸汽吸附仪SMS DVS Advantage dynamic vapor adsorption instrument
实验方法：experimental method:
取式(II)化合物A晶型10～15mg置于DVS样品盘内进行测试。Take 10-15 mg of compound A crystal form of formula (II) and place it in a DVS sample tray for testing.
实验结果：Experimental results:
式(II)化合物A晶型的DVS谱图如图3所示，△W＝0.29％。The DVS spectrum of compound A crystal form of formula (II) is shown in Figure 3, ΔW=0.29%.
实验结论：Experimental results:
式(II)化合物A晶型在25℃和80％RH下的吸湿增重为0.29％，略有吸湿性。The hygroscopic weight gain of compound A crystal form of formula (II) at 25° C. and 80% RH is 0.29%, which is slightly hygroscopic.
生物测试数据biological test data
实验例1：果糖激酶实验(KHK assay)Experimental Example 1: Fructose Kinase Assay (KHK assay)
A.主要材料A.Main material
1.EnVision酶标仪，珀金埃尔默；1. EnVision microplate reader, PerkinElmer;
2.OptiPlate 384微孔板，珀金埃尔默，货号：6007290；2. OptiPlate 384 microplate, PerkinElmer, catalog number: 6007290;
3.重组人果糖激酶(KHK)，R&D_货号：8177-HK-020，批次号：DDFK0117092；3. Recombinant human fructokinase (KHK), R&D_article number: 8177-HK-020, batch number: DDFK0117092;
4.果糖(D(-)-Fructose)，国药_货号：36003034；4. Fructose (D(-)-Fructose), Sinopharm_Product No.: 36003034;
5.ADP-Glo试剂盒，Promega_货号：V9101。5. ADP-Glo kit, Promega_product number: V9101.
B.方法B. method
a)激酶反应a) Kinase reaction
1.配制缓冲液：包含50mM羟乙基哌嗪乙硫磺酸(Hepes)，140mM KCl，3.5mM MgCl2，0.01％牛血清白蛋白(BSA)，pH值为7.4。1. Preparation buffer: containing 50mM hydroxyethylpiperazine ethanesulfonic acid (Hepes), 140mM KCl, 3.5mM MgCl2, 0.01% bovine serum albumin (BSA), pH value is 7.4.
2.用缓冲液配制2.5倍浓度的果糖激酶工作液，其中果糖激酶是50nM,果糖是12.5mM。2. Prepare 2.5-fold concentration of fructokinase working solution with buffer solution, in which fructokinase is 50nM and fructose is 12.5mM.
3.用缓冲液配制2.5倍浓度的三磷酸腺苷(ATP)工作液，浓度为250μM。3. Prepare a 2.5-fold concentration of adenosine triphosphate (ATP) working solution with a buffer solution, and the concentration is 250 μM.
4.稀释化合物从500μM的浓度开始，3倍稀释9个浓度点，化合物在反应体系的终浓度从10μM开始，二甲基亚砜(DMSO)的终浓度为2％。4. Dilution The compound starts from a concentration of 500 μM, and is diluted 3 times to 9 concentration points. The final concentration of the compound in the reaction system starts from 10 μM, and the final concentration of dimethyl sulfoxide (DMSO) is 2%.
5.准备一块96孔板作为反应板，加入每孔6μL的2.5倍浓度的果糖激酶工作液，再加入每孔3μL的化合物工作液之后，在室温下孵育5分钟。5. Prepare a 96-well plate as a reaction plate, add 6 μL of 2.5-fold concentration of fructokinase working solution to each well, then add 3 μL of compound working solution to each well, and incubate at room temperature for 5 minutes.
6.每行第一个孔为化合物的阳性对照，即加入相同体积的缓冲液来替代化合物和果糖激酶；最后一个孔为化合物的阴性对照，即加入相同体积的缓冲液来替代化合物。6. The first well of each row is the positive control of the compound, that is, add the same volume of buffer to replace the compound and fructokinase; the last well is the negative control of the compound, that is, add the same volume of buffer to replace the compound.
7.在96孔反应板中每孔加入6μL的ATP工作液之后启动激酶反应。激酶反应在28℃恒温加热器孵育1小时。7. Start the kinase reaction after adding 6 μL of ATP working solution to each well of the 96-well reaction plate. Kinase reactions were incubated for 1 hour at 28°C in a thermostatic heater.
b)ADP-Glo检测b) ADP-Glo detection
1.准备一块384板作为检测板，先加入5μL的ADP-Glo试剂。1. Prepare a 384 plate as a test plate, first add 5 μL of ADP-Glo reagent.
2.每孔加入5μL反应板中的激酶反应混合物，在28℃恒温加热器孵育30分钟。2. Add 5 μL of the kinase reaction mixture in the reaction plate to each well, and incubate at 28°C for 30 minutes.
3.每孔加入10μL激酶检测试剂，在28℃恒温加热器孵育30分钟。3. Add 10 μL of Kinase Detection Reagent to each well and incubate at 28°C for 30 minutes.
4.将检测板放入EnVision酶标仪中读化学发光信号。4. Put the detection plate into the EnVision microplate reader to read the chemiluminescence signal.
C.实验结果：C. Experimental results:
表2:KHK体外活性测试结果Table 2: KHK in vitro activity test results
化合物编号Compound number KHK IC 50 KHK IC 50
式I化合物Compound of formula I 37nM37nM
结论：式I化合物对人源KHK酶具有很强的抑制活性。Conclusion: the compound of formula I has strong inhibitory activity on human KHK enzyme.

Claims (12)

  1. 式(II)化合物，A compound of formula (II),
    Figure PCTCN2022099375-appb-100001
    Figure PCTCN2022099375-appb-100001
  2. 式(II)化合物的A晶型，其特征在于其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：9.73±0.20°，11.22±0.20°，12.66±0.20°，18.38±0.20°。The crystal form A of the compound of formula (II) is characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.73±0.20°, 11.22±0.20°, 12.66±0.20°, 18.38±0.20°.
  3. 根据权利要求2所述的A晶型，其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：6.94±0.20°，9.73±0.20°，11.22±0.20°，12.66±0.20°，15.63±0.20°，16.62±0.20°，18.38±0.20°，20.81±0.20°。The crystal form A according to claim 2, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 6.94±0.20°, 9.73±0.20°, 11.22±0.20°, 12.66±0.20°, 15.63±0.20 °, 16.62±0.20°, 18.38±0.20°, 20.81±0.20°.
  4. 根据权利要求3所述的A晶型，其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：6.46±0.20°，6.94±0.20°，9.73±0.20°，11.22±0.20°，12.66±0.20°，15.63±0.20°，16.62±0.20°，18.38±0.20°，19.64±0.20°，20.81±0.20°，22.51±0.20°，24.58±0.20°。The crystal form A according to claim 3, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 6.46±0.20°, 6.94±0.20°, 9.73±0.20°, 11.22±0.20°, 12.66±0.20 °, 15.63±0.20°, 16.62±0.20°, 18.38±0.20°, 19.64±0.20°, 20.81±0.20°, 22.51±0.20°, 24.58±0.20°.
  5. 根据权利要求4所述的A晶型，其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：4.47±0.20°，6.46±0.20°，6.94±0.20°，9.73±0.20°，11.22±0.20°，12.25±0.20°，12.66±0.20°，15.63±0.20°，16.62±0.20°，17.83±0.20°，18.38±0.20°，19.64±0.20°，20.81±0.20°，22.51±0.20°，23.59±0.20°，24.58±0.20°。According to the crystal form A according to claim 4, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 4.47±0.20°, 6.46±0.20°, 6.94±0.20°, 9.73±0.20°, 11.22±0.20 °, 12.25±0.20°, 12.66±0.20°, 15.63±0.20°, 16.62±0.20°, 17.83±0.20°, 18.38±0.20°, 19.64±0.20°, 20.81±0.20°, 22.51±0.20°, 23.59±0.20 °, 24.58±0.20°.
  6. 根据权利要求5所述的A晶型，其X射线粉末衍射图谱在下列2θ角处具有特征衍射峰：4.47°，6.46°，6.94°，9.73°，10.18°，11.22°，12.25°，12.66°，13.30°，14.30°，15.63°，16.62°，17.27°，17.83°，18.38°，18.67°，19.37°，19.64°，20.06°，20.41°，20.81°，21.72°，22.51°，23.59°，24.58°，25.11°，26.44°，27.41°，27.99°，29.40°，30.85°。According to the crystal form A according to claim 5, its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 4.47°, 6.46°, 6.94°, 9.73°, 10.18°, 11.22°, 12.25°, 12.66° , 13.30°, 14.30°, 15.63°, 16.62°, 17.27°, 17.83°, 18.38°, 18.67°, 19.37°, 19.64°, 20.06°, 20.41°, 20.81°, 21.72°, 22.51°, 23.59°, 24.58 °, 25.11°, 26.44°, 27.41°, 27.99°, 29.40°, 30.85°.
  7. 根据权利要求2～6中任一项所述的A晶型，其差示扫描量热曲线在188.5℃±3.0℃处有一个吸热峰的峰值。According to the crystal form A described in any one of claims 2-6, its differential scanning calorimetry curve has an endothermic peak at 188.5°C±3.0°C.
  8. 根据权利要求7所述的A晶型，其DSC图谱如图2所示。According to the crystal form A according to claim 7, its DSC spectrum is as shown in Fig. 2 .
  9. 根据权利要求2～6中任一项所述的A晶型，其热重分析曲线在150.0℃±3.0℃时失重达1.56％。According to any one of claims 2-6, the crystal form A has a weight loss of 1.56% at a thermogravimetric analysis curve at 150.0°C±3.0°C.
  10. 根据权利要求9所述的A晶型，其TGA图谱如图3所示。The crystal form A according to claim 9, whose TGA spectrum is as shown in FIG. 3 .
  11. 式(II)化合物A晶型的制备方法，包括：The preparation method of compound A crystal form of formula (II), comprising:
    Figure PCTCN2022099375-appb-100002
    Figure PCTCN2022099375-appb-100002
    (a)将式(I)化合物加入醇类溶剂中溶解；(a) adding the compound of formula (I) to dissolve in an alcoholic solvent;
    (b)在搅拌下缓慢加入甜菜碱和醇类溶剂的混合溶液；(b) slowly add the mixed solution of betaine and alcoholic solvent under stirring;
    (c)20～30℃下搅拌8～16小时；(c) stirring at 20 to 30°C for 8 to 16 hours;
    (d)过滤后干燥8～16小时；(d) drying for 8 to 16 hours after filtration;
    其中，所述醇类溶剂选自异丙醇，乙醇和甲醇。Wherein, the alcoholic solvent is selected from isopropanol, ethanol and methanol.
  12. 根据权利要求1所述的化合物、或根据权利要求2～9中任意一项所述的A晶型、或根据权利要求10所述的方法制备得到的晶型在制备治疗非酒精性脂肪性肝炎(NASH)的药物中的应用。The compound according to claim 1, or the crystal form A according to any one of claims 2 to 9, or the crystal form prepared according to the method according to claim 10 is used in the preparation and treatment of nonalcoholic steatohepatitis (NASH) drug application.
PCT/CN2022/099375 2021-06-17 2022-06-17 Salt form and crystal form of spiro compound and preparation method therefor WO2022262841A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280042743.8A CN117677615A (en) 2021-06-17 2022-06-17 Salt form and crystal form of spiro compound and preparation method thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110672236.X 2021-06-17
CN202110672236 2021-06-17

Publications (1)

Publication Number Publication Date
WO2022262841A1 true WO2022262841A1 (en) 2022-12-22

Family

ID=84526891

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/099375 WO2022262841A1 (en) 2021-06-17 2022-06-17 Salt form and crystal form of spiro compound and preparation method therefor

Country Status (2)

Country Link
CN (1) CN117677615A (en)
WO (1) WO2022262841A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108473469A (en) * 2015-12-29 2018-08-31 辉瑞公司 Substituted 3- azabicyclos [3.1.0] hexane as ketohexokinase fructokinase inhibitor
CN111423420A (en) * 2020-04-30 2020-07-17 广州博济医药生物技术股份有限公司 Fused ring compounds as ketohexokinase inhibitors
WO2020156445A1 (en) * 2019-01-29 2020-08-06 山东轩竹医药科技有限公司 Hexone glucokinase inhibitor and use thereof
CN111978296A (en) * 2019-05-22 2020-11-24 山东轩竹医药科技有限公司 Ketohexokinase inhibitors and uses thereof
WO2021129737A1 (en) * 2019-12-24 2021-07-01 南京明德新药研发有限公司 Compound having khk inhibitory effect

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108473469A (en) * 2015-12-29 2018-08-31 辉瑞公司 Substituted 3- azabicyclos [3.1.0] hexane as ketohexokinase fructokinase inhibitor
WO2020156445A1 (en) * 2019-01-29 2020-08-06 山东轩竹医药科技有限公司 Hexone glucokinase inhibitor and use thereof
CN111978296A (en) * 2019-05-22 2020-11-24 山东轩竹医药科技有限公司 Ketohexokinase inhibitors and uses thereof
WO2021129737A1 (en) * 2019-12-24 2021-07-01 南京明德新药研发有限公司 Compound having khk inhibitory effect
CN111423420A (en) * 2020-04-30 2020-07-17 广州博济医药生物技术股份有限公司 Fused ring compounds as ketohexokinase inhibitors

Also Published As

Publication number Publication date
CN117677615A (en) 2024-03-08

Similar Documents

Publication Publication Date Title
ES2900263T3 (en) Cystic fibrosis transmembrane conductance regulator modulator, pharmaceutical compositions, treatment methods and modulator manufacturing process
ES2524826T3 (en) Procedure for the purification of {4,6-diamino-2- [1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b] pyridin-3-yl] pyrimidin-5-yl} methylcarbamate methyl
BR112021003727A2 (en) salts and crystal forms of positive allosteric modulator for gabaa
CA2963581C (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
KR20140138941A (en) Salts of an epidermal growth factor receptor kinase inhibitor
TWI718197B (en) 4h-pyrazolo [1,5-a] benzimidazoles and their preparation method and intermediates
WO2021098850A1 (en) Crystal form of nucleoprotein inhibitor and use thereof
JP6974618B2 (en) Salt form, crystalline form and method for producing the compound as an FGFR and VEGFR inhibitor.
WO2018041260A1 (en) Bromodomain recognition protein inhibitor and preparation method therefor and use thereof
WO2022262841A1 (en) Salt form and crystal form of spiro compound and preparation method therefor
WO2022179577A1 (en) Crystal form of cyclopropyl-substituted benzofuran compound and preparation method therefor
KR20200097771A (en) Salt forms and crystal forms thereof as Akt inhibitors
JP7118354B2 (en) Crystal forms of tricyclic compounds and uses thereof
US20220162185A1 (en) Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
JP2022523035A (en) 1,2,3-Triazolo [1,5-a] Pyrazine derivative crystal form and method for preparing the crystal form
WO2019020068A1 (en) Crystalline or amorphous form of steroid derivative fxr agonist, preparation method therefor and use thereof
TWI826013B (en) Crystal forms of imidazolinone derivatives
WO2021043200A1 (en) Method for preparing quinazoline derivative and crystallization thereof
WO2021139794A1 (en) Crystal form of pyrrolidinyl urea derivative and application thereof
WO2021023271A1 (en) Crystal form of compound as prostacyclin receptor agonist and preparation method therefor
RU2787767C2 (en) Benzoxazole derivative crystal
RU2800751C2 (en) Crystalline or amorphous form of fxr agonists being steroid derivatives, their production method and their use
WO2018223836A1 (en) Crystal form of fatty acid bile acid conjugate, method for preparing same, and application
WO2020088677A1 (en) Angiotensin ii receptor 2 antagonist salt form and crystalline form, and preparation method therefor
WO2019141245A1 (en) Crystal and salt forms of tricyclic compound and preparation method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22824313

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280042743.8

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22824313

Country of ref document: EP

Kind code of ref document: A1